Jeff Liu (@jeffliuing) header
Jeff Liu (@jeffliuing) profile picture

Co-founder & the Dude @ FinalDose (YC P26) PhD @ Oxford Oncology Ending all cancers

San Francisco, CA
Joined February 2016
Photo by Jeff Liu (@jeffliuing)Photo by Jeff Liu (@jeffliuing)Photo by Jeff Liu (@jeffliuing)Photo by Jeff Liu (@jeffliuing)Photo by Jeff Liu (@jeffliuing)Photo by Jeff Liu (@jeffliuing)Photo by Jeff Liu (@jeffliuing)Photo by Jeff Liu (@jeffliuing)Photo by Jeff Liu (@jeffliuing)Photo by Jeff Liu (@jeffliuing)
FinalDose: We’re going to end cancer in the open We plan to build FinalDose as public as we possibly can and write up as we go, including the parts that don’t survive! Please help spread the word: @FinalDoseLFG substack.com/@finaldose
7
12
5
54
4,561
My Taiwanese bro please come backkk
Over the past week, I’ve been overwhelmed by the love and support of friends, industry colleagues, and people I've never met. Thank you to everyone who has shown kindness to my family and me. It means the world to me. I came to the United States 53 years ago, and becoming an American citizen is one of the greatest gifts and proudest moments of my life. NVIDIA has been my life’s work. Building it into the company it is today alongside my colleagues has been a privilege and an honor. Nowhere but in America could a company like NVIDIA be possible. I love our country, and I love NVIDIA. I did not live up to the standards expected of everyone at NVIDIA, and I have made serious mistakes in my personal life. I created problems for the Board that I deeply regret. I own my mistakes completely, and I am committed to cooperating with the Board’s independent investigation. Since my departure, I’ve seen an outpouring of calls from NVIDIA’s employees, investors, business partners, and customers for me to return as CEO. Many continue to reach out to me directly as the company navigates complex technology, market, competitive, and geopolitical dynamics. NVIDIA is a once-in-a-generation company. If the Board of Directors decides that my return is in the best interest of our shareholders, our employees, the company, and America, I would be honored to answer these calls and return as CEO. Thank you again to everyone who has shared their good wishes. I am profoundly humbled by your support. To my family: I love you, and I will spend the rest of my life being worthy of yours. Jensen
70
What a legend, congratssssss @IsomorphicLabs and @demishassabis He's done it Crazyyy time to be alive building a biotech company, never seen this level of optimism, lets take these capital and actually do something awesome to humanity please
Thrilled to announce $5B in funding for @IsomorphicLabs to accelerate our mission to Solve All Disease. We continue to make rapid progress reimagining drug design from first principles with AI to radically cut the time & cost to find new medicines. Gradually, then all at once...
1
16
649
Thrilled to announce $5B in funding for @IsomorphicLabs to accelerate our mission to Solve All Disease. We continue to make rapid progress reimagining drug design from first principles with AI to radically cut the time & cost to find new medicines. Gradually, then all at once...
481
1,051
297
10,465
456,487
Odd observation but I feel like a lot of the non defense deep tech in @ycombinator are from founders outside of US
2
122
Replying to @kristinahoang_
I gotta agree
1
22
6/6 We both share a huge excitement for the next wave of precision oncology-and completely nerded out on programmable, sequence-activated cancer therapies like what we're building at @FinalDoseLFG Grateful to learn from one of the greats who paved the way.
1
18
5/6 In 2015, Alan moved to San Francisco to lead the UCSF Helen Diller Family Comprehensive Cancer Center, where I got to sit down with him yesterday. Incredibly sharp, generous with his time, and deeply thoughtful about where the field is heading.
1
1
28
4/6 That 2005 paper went all the way from bench to bedside. In December 2014, the FDA approved Olaparib for BRCA-mutated ovarian cancer. Today, PARP inhibitors are used across breast, prostate, and pancreatic cancers- playing a role in roughly 5% of all cancer treatments.
1
1
27
3/6 The mechanism behind it is called synthetic lethality: BRCA-deficient cancer cells can't repair DNA breaks via homologous recombination. Block PARP, and they can't keep up so they die. • Healthy cells still have their backup DNA repair pathway and survive. It gave us a way to selectively kill cancer using a genetic vulnerability that normal cells don't have.
1
1
30
2/6 In 1995, Alan was part of the team at the Institute of Cancer Research (ICR) in London that identified BRCA2, the second-biggest breast cancer susceptibility gene. A decade later in 2005, his lab published a landmark Nature paper showing that cells missing BRCA1 or BRCA2 were ~1,000x more sensitive to PARP inhibition than normal cells.
1
2
60
Had a long chat yesterday with legendary cancer scientist Alan Ashworth. If you know anyone who's taken a PARP inhibitor, Alan's lab is a massive reason that drug exists. Here's how his work changed modern oncology and what comes next
2
12
436
Cost of flight change is greater than buying a new ticket is pure wilderness
1
97
Jeff Liu retweeted
The pharma folks are right to call out Dario for making bold claims about curing all disease. They are also right that most necessary bio data does not yet exist. Still, pharma has two crucial blindspots: 1) The industry has never witnessed what a small, well capitalized, and well incentivized silicon valley team can do (no instagram, whatsapp, ARM, cursor in pharma). They grossly underestimate what's coming for them. 2) They don't yet see just how much the labs *need* to win in bio to double TAM (there simply is not other accessible market), and just how much all of tech's liquidity relies on this happening. Pharma is a risk management industry: you get fired for failing in old ways, not for failing in new ways. The industry will be shocked at how fast automated labs, better models, etc can be stood up by small, well capitalized teams that have only 1x to lose and thousands of x to gain. Pharma doesn't quite yet have a traditional innovator's dillema. Their capital and GTM moats are still deep, but not for much longer (drugs going d2c, dev costs decreasing). Pharma's window to win is open, but it will close fast if they fail to take ownership of the incoming infrastructure explosion.
38
15
10
170
23,273
Lets gooo
This letter was sent to Nvidia's board today. A first for @atreidesmgmt Absolutely share @altcap belief that this letter outlines minimum acceptable standards.
112
Jeff Liu retweeted
New episode of HARD DRUGS! Will AI progress be crushed by Eroom’s law? Even as technology has advanced, drug development has gotten more and more expensive over time. In the 1950s, one billion dollars of R&D spending got us roughly fifty new drugs. Today, it gets us about one. This trend is called Eroom’s law, or Moore’s law spelled backwards. It seems pretty bleak: the R&D cost per new drug has roughly doubled every nine years, in inflation-adjusted dollars, meaning drug development has become exponentially more expensive. What could explain this? Here are some possibilities: • Our standards of evidence and requirements for safety testing have risen, through regulation, public expectations, and risk aversion. • We’ve picked the low-hanging fruit already. Perhaps we’ve already made the easiest discoveries, and diseases that are harder to understand or treat are left. • Or perhaps it’s the ‘better than the Beatles’ problem: New drugs not only have to be effective, but have to compete with existing treatments, which are already effective. Plus, some of them have gone off-patent and become cheap generics, making the price contrast starker. Relatedly, as diseases become rarer or milder, it takes more effort to demonstrate that new drugs are effective, with larger or longer clinical trials. But there are also reasons to question these explanations. We still lack effective treatments for many diseases. And our tools for studying biology have improved enormously. Why hasn’t that been enough? Will our best efforts be crushed by Eroom’s law, too? Or can AI reverse the trend? In our latest episode of HARD DRUGS, @JacobTref and I chat about all this and more. Listen wherever you get your podcasts! Chapters: 00:00 Introduction 02:53 Eroom’s law trivia 12:33 How much does it really cost to develop a drug? 22:35 The better than the Beatles problem 33:06 Clinical trials are larger and more rigorous today 42:01 Have we picked the low-hanging fruit? 01:01:22 Is Eroom’s law slowing down because of rare disease drugs? 01:06:18 Can AI reverse Eroom’s law? 01:15:09 Conclusion
15
20
7
159
48,664
Jeff Liu retweeted
Jensen
" You're gonna be remembered forever because some things are eternal."
6,240
13,585
1,294
152,812
12,750,536
Jeff Liu retweeted
I analyzed eleven New York Times reports on the Jensen Huang story. Most notably, NYT makes the "spy" claim 30 times in these 11 reports. The original report cites unnamed officials who had been "briefed" on the intelligence. Not who had seen it themselves -- but who had been "briefed". This is a game of telephone with plausible deniability. Nobody named. No specific details of the intelligence used to draw the conclusion that the woman was a spy. Anonymous "officials" "briefed". This was used to try to take Jensen Huang down. When that didn't work, journalists resorted to viciously digging up and scandal mongering about Jensen Huang's other alleged affairs. Then he was removed as CEO. Without an investigation. Without due process. And now officials and intelligence agencies are contesting the New York Times characterization. This is unethical. It is unjust. It is an absolute disgrace. If anyone should resign now, it is Nvidia's board who aggressively removed Jensen Huang without an investigation, after he gave decades of his life to make the company what it is. And any investigation that proceeds from here should involved not just the "spy" claim, but the New York Times -- who has engaged in potentially unethical behavior. Jensen Huang deserves due process -- not mob justice. He deserves respect for everything he has done for technology and America -- not a disgraceful removal after anonymous, unsubstantiated allegations, several parties removed from the source.
Bombshell story. The spy narrative is collapsing already. Is there clear & convincing evidence that Alice Huang was a Chinese spy? - AG says no. (“no conclusions reached”). - CIA says no. (“not yet convinced”). - DNI says no (“not entirely accurate and over-torqued”). - Ranking Democrat on House Intelligence (incoming Chairman) says no. (“today, at least, I don’t know”). This was immediately after he was briefed. Who argues otherwise? Anonymous officials tell CNN “it strains credulity to believe that she was not acting as an agent of the Chinese government — simply by virtue of the fact that she is a successful Chinese businesswoman working with one of America’s most powerful companies.” This is their proof after a year of investigating and surveillance? That she was a “successful Chinese businesswoman”? At this point, the only crime that we know for sure happened is the leaking of the classified memo. Who did that and why? An investigation should be opened.
276
1,000
108
4,542
185,790
Replying to @JensenHuang
@JensenHuang please pull a Sam Altman 2.0 please
4
143